TL;DR
This paper investigates Ociperlimab (BGB-A1217), a novel anti-TIGIT antibody, demonstrating its potent anti-tumor activity in preclinical models. Crucially, the study highlights that the antibody's Fc effector function, which enables interactions with immune cells like NK cells and macrophages, is essential for its efficacy, particularly in reducing immunosuppressive regulatory T cells (Tregs).
What Problem Does This Paper Address?
Cancer immunotherapy has revolutionized treatment, but many patients don't respond or develop resistance. Immune checkpoints, like PD-1 and TIGIT, are key targets because they act as "brakes" on the immune system, preventing it from attacking cancer cells. TIGIT, expressed on T cells, NK cells, and Tregs, plays a significant role in suppressing anti-tumor immunity by interacting with its ligands (PVR and PVR-L2). While blocking TIGIT is a promising strategy, the specific role of the antibody's "Fc region" – the part that interacts with other immune cells – in mediating anti-tumor effects has been unclear. Different therapeutic antibodies utilize Fc regions with varying effector functions (e.g., wild-type IgG1, Fc-silent variants). This paper aims to elucidate the contribution of Fc effector function to the anti-TIGIT antibody's efficacy and to characterize the mechanisms by which it exerts its anti-tumor effects.
Methods
The researchers generated two versions of the anti-TIGIT antibody, BGB-A1217: one with a wild-type IgG1 Fc region (competent effector function) and another with a modified Fc region designed to lack FcyR binding (Fc-silent). They then employed a multi-pronged approach:
- Binding Assays: Surface Plasmon Resonance (SPR) and flow cytometry were used to confirm BGB-A1217's high affinity binding to TIGIT and its ability to block TIGIT-ligand interactions. They also assessed binding to various Fcy receptors.
- In Vitro Functional Assays:
- T-cell Activation: CMV-specific T cells were co-cultured with target cells in the presence of the antibodies to measure IFN-γ secretion, a marker of T-cell activation.
- ADCC (Antibody-Dependent Cellular Cytotoxicity): NK cell lines and primary NK cells were used to assess the antibody's ability to kill TIGIT-expressing target cells, particularly Tregs.
- NK and Monocyte Activation: NK cells and monocytes were incubated with the antibodies to measure activation markers (e.g., CD107a, CD86).
- Trogocytosis: This assay measured the removal of TIGIT from cell surfaces by FcyR-bearing cells, indicating an Fc-dependent mechanism.
- In Vivo Efficacy Studies:
- Tumor Models: Syngeneic mouse models (CT26.WT, MC38, Renca) and human TIGIT knock-in mouse models were used to evaluate the anti-tumor efficacy of BGB-A1217, both as a single agent and in combination with an anti-PD-1 antibody.
- Pharmacodynamic Analysis: Tumor-infiltrating lymphocytes were analyzed post-treatment to assess changes in TIGIT expression, Treg frequency, and DNAM-1 expression.
Datasets
The study utilized established cell lines (e.g., BW5147.3, HEK293, HCT116, A549, NK92MI, SK-BR-3, Jurkat, CT26.WT, Renca) and primary human PBMCs from healthy donors and cancer patients. For in vivo studies, mice (BALB/c, and human TIGIT knock-in mice) were used. No new benchmark datasets were introduced.
Key Insights and Ideas
- Fc Function is Crucial for Anti-TIGIT Efficacy: The most striking finding is that the Fc effector function of BGB-A1217 is not merely additive but critical for its potent anti-tumor activity. The Fc-silent version showed significantly reduced efficacy.
- Treg Depletion as a Key Mechanism: BGB-A1217, through its Fc function, preferentially depletes immunosuppressive Tregs, a mechanism that appears vital for its anti-tumor effects. This is particularly interesting given the higher expression of TIGIT on Tregs.
- Multi-Modal Action: BGB-A1217 doesn't just block TIGIT; it actively engages the immune system through multiple Fc-dependent mechanisms: ADCC against Tregs, activation of NK cells and monocytes, and trogocytosis (removal of TIGIT from cell surfaces).
- Synergy with Anti-PD-1: Combining BGB-A1217 with an anti-PD-1 antibody demonstrated enhanced anti-tumor efficacy, suggesting a powerful therapeutic strategy for cancer.
- Trogocytosis and DNAM-1 Upregulation: The removal of TIGIT from T cells via trogocytosis might not only relieve TIGIT-mediated inhibition but also potentially enhance the function of DNAM-1, a co-stimulatory molecule.
Key Results
- BGB-A1217 binds to human TIGIT with high affinity (K<sub>D</sub> = 0.135 nM) and specifically blocks TIGIT's interaction with PVR and PVR-L2.
- In vitro, BGB-A1217 significantly enhances T-cell functions, as evidenced by increased IFN-γ secretion.
- BGB-A1217 induces potent ADCC against Treg cells in cancer patient PBMCs, a function absent in the Fc-silent variant.
- BGB-A1217 activates NK cells and monocytes in an Fc-dependent manner.
- In vivo, BGB-A1217 demonstrated significant anti-tumor efficacy in both single-agent and combination therapy (with anti-PD-1) settings in preclinical models. The Fc-silent version showed minimal efficacy.
- Treatment with BGB-A1217 led to a significant reduction in intra-tumoral Treg frequencies and down-regulation of TIGIT, along with an up-regulation of DNAM-1 on T cells and NK cells.
Limitations and Future Work
- Human vs. Mouse Models: While human TIGIT knock-in mice were used, the study acknowledges that the full translation of Fc-mediated effects from mouse to human can be complex due to differences in FcyR polymorphisms.
- FcyR Polymorphisms: The authors note that human FcyR polymorphisms can impact the efficacy of IgG1 antibodies, suggesting a need for patient stratification based on these polymorphisms in future clinical trials.
- Clinical Translation: The study strongly supports the clinical development of BGB-A1217, particularly with its effector-competent Fc region. Further clinical studies are needed to confirm these mechanisms in humans and to explore optimal combination strategies.
- Myeloid Cell Modulation: While myeloid cell activation was observed in vitro, further investigation is needed to fully delineate the extent and mechanisms of BGB-A1217's modulation of myeloid cells in vivo.
Summary updated